News

Neeraj Akhoury, Shree Cement On CNBC-TV18:

Following Value Over Volumes Strategy For The Company

Will See 4-5% Volume Growth In FY26

Maintaining The Revenue Growth Guidance Of 9% For FY26

Will Maintain The Market Share For FY26

Ebitda/ tn guidance on Rs1350-1400 for FY26

Prefer Organic Growth Vs Inorganic Growth

We Are Interested In Deccan cement & JP Cement But Only At The Right Price

Believe The UAE Numbers Are Sustainable Given The Good Demand For The Products

Price Growth Has Been 9% YoY& EBITDA/ tonne Is 45% YoY In Q1FY26

KPI Green Q1

Net Profit up 68.4% At Rs 111.3 Cr Vs Rs 66 Cr (YoY)

Revenue up 73% At Rs 603 Cr Vs Rs 348 Cr (YoY)

EBITDA up 55.6% At Rs206 Cr Vs Rs 132.5 Cr (YoY)

Margin At 34.2% Vs 38% (YoY)

Aurobindo Pharma shares are down 1.27% at the moment.

The company posted a consolidated net profit of ₹824.2 crore, down 10.2% year-on-year from ₹918.2 crore. This was below the CNBC-TV18 poll estimate of ₹919.3 crore. Revenue for the quarter stood at ₹7,868 crore, reflecting a 4% rise from ₹7,567 crore in the same period last year. However, this too fell short of analysts’ projection of ₹8,215 crore. On the operating front, earnings before interest, tax, depreciation and amortisation (EBITDA) remained stable, falling 1% YoY to ₹1,603 crore from ₹1,619.6 crore, against a CNBC-TV18 estimate of ₹1,730 crore.

Welcome to CNBC-TV18’s blog on Q1 earnings. Check this space for LIVE updates on earnings, management commentary, stock reaction, and more.NewsLive TVMarketPopular CategoriesCalculatorsTrending NowLet's Connect with CNBCTV 18Network 18 Group :©TV18 Broadcast Limited. All rights reserved.